Risk factors
Geron (GERN) risk factors
Item 1A of every Geron Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors60 risks20 new14 dropped26 reworded
RYTELO is now approved in the EU, adding EU commercialization, reimbursement, orphan-exclusivity, and regulatory risks.
Filed Mar 02, 2026 - FY2024 10-K risk factors74 risks
Geron is a commercial-stage biopharmaceutical company wholly dependent on the success of its sole approved product, RYTELO (imetelstat). The company faces major risks regarding sales execution, manufacturing supply chains, reimbursement, and heavy indebtedness under its Pharmakon loan.
Filed Feb 27, 2025